Literature DB >> 29561664

miRNA-34a decreases ovarian cancer cell proliferation and chemoresistance by targeting HDAC1.

Teng Lv1,2, Kejuan Song2, Lili Zhang3, Weihua Li2, Yulong Chen2, Yuchao Diao2, Qin Yao2, Peishu Liu1.   

Abstract

This study aimed to explore the roles of miRNA-34a (miR-34a) in ovarian cancer (OC) cells and uncover possible mechanisms. The proliferation of OC cells was measured with an MTT assay and soft agar colony formation assay. TargetScan analysis, real-time PCR, and a luciferase reporter assay were used to demonstrate the downstream target of miR-34a in OC cells. HDAC1 expression levels were detected by immunoblot analysis. miR-34a inhibited the proliferation of SKOV3 and OVCA433 cells and enhanced cisplatin sensitivity in cisplatin-resistant SKOV3cp cells. The results of TargetScan analysis, real-time PCR, and luciferase reporter assay confirmed that miR-34a downregulated HDAC1 expression by directly targeting the 3'-UTR of HDAC1 mRNA. The overexpression of HDAC1 decreased cisplatin sensitivity and promoted proliferation in OC cells. MTT assay and soft agar colony formation assay showed that HDAC1 overexpression blocked the suppressive effects of miR-34a on SKOV3 cell proliferation. In addition, treatment with the miR-34a mimic partially recovered the cisplatin sensitivity of SKOV3cp cells, whereas HDAC1 overexpression blocked the above phenomena caused by treatment with the miR-34a mimic. miR-34a exhibited suppressive effects on OC cells via directly binding and downregulating HDAC1 expression, which subsequently decreased the resistance to cisplatin and suppressed proliferation in OC cells.

Entities:  

Keywords:  HDAC1; anti-prolifération; antiproliferation; cancer ovarien; cisplatin resistance; miR-34a; ovarian cancer; résistance au cisplatine

Mesh:

Substances:

Year:  2018        PMID: 29561664     DOI: 10.1139/bcb-2018-0031

Source DB:  PubMed          Journal:  Biochem Cell Biol        ISSN: 0829-8211            Impact factor:   3.626


  17 in total

1.  Human bone marrow-derived mesenchymal stem cell-secreted exosomes overexpressing microRNA-34a ameliorate glioblastoma development via down-regulating MYCN.

Authors:  Bin Wang; Zhong-Hua Wu; Ping-Yang Lou; Chang Chai; Shuang-Yin Han; Jian-Fang Ning; Ming Li
Journal:  Cell Oncol (Dordr)       Date:  2019-07-22       Impact factor: 6.730

Review 2.  Mir-34a: a regulatory hub with versatile functions that controls osteosarcoma networks.

Authors:  Zhimin Yang; Tang Liu; Xiaolei Ren; Mei Yang; Chao Tu; Zhihong Li
Journal:  Cell Cycle       Date:  2022-06-14       Impact factor: 5.173

Review 3.  A comprehensive survey into the role of microRNAs in ovarian cancer chemoresistance; an updated overview.

Authors:  Ahmad Saburi; Mohammad Saeed Kahrizi; Navid Naghsh; Hasti Etemadi; Ahmet İlhan; Ali Adili; Shadi Ghoreishizadeh; Rozita Tamjidifar; Morteza Akbari; Gülinnaz Ercan
Journal:  J Ovarian Res       Date:  2022-07-07       Impact factor: 5.506

4.  miR-3614-3p suppresses cell aggressiveness of human breast cancer by targeting AKT3 and HDAC1 expression.

Authors:  Zhenzhen Wang; Xintao Jing; Fang Li; Yanke Chen; Chen Huang
Journal:  Transl Cancer Res       Date:  2022-06       Impact factor: 0.496

Review 5.  The comprehensive landscape of miR-34a in cancer research.

Authors:  Sijing Li; Xiaohui Wei; Jinyong He; Quanquan Cao; Danyu Du; Xiaoman Zhan; Yuqi Zeng; Shengtao Yuan; Li Sun
Journal:  Cancer Metastasis Rev       Date:  2021-05-06       Impact factor: 9.264

6.  MicroRNA-126 exerts antitumor functions in ovarian cancer by targeting EGFL7 and affecting epithelial-to-mesenchymal transition and ERK/MAPK signaling pathway.

Authors:  Yuhua Zhang; Xiaobo Qin; Juan Jiang; Wenjie Zhao
Journal:  Oncol Lett       Date:  2020-05-29       Impact factor: 2.967

7.  MicroRNA-34a/IL-6R pathway as a potential therapeutic target for ovarian high-grade serous carcinoma.

Authors:  Ryo Yokomizo; Nozomu Yanaihara; Noriko Yamaguchi; Misato Saito; Ayako Kawabata; Kazuaki Takahashi; Masataka Takenaka; Kyosuke Yamada; Jason Solomon Shapiro; Aikou Okamoto
Journal:  Oncotarget       Date:  2019-08-06

Review 8.  Role of non-coding RNAs and RNA modifiers in cancer therapy resistance.

Authors:  Xinyi Zhang; Kai Xie; Honghua Zhou; Yuwei Wu; Chan Li; Yating Liu; Zhaoya Liu; Qian Xu; Shuang Liu; Desheng Xiao; Yongguang Tao
Journal:  Mol Cancer       Date:  2020-03-02       Impact factor: 27.401

9.  miR-141-3p and TRAF5 Network Contributes to the Progression of T-Cell Acute Lymphoblastic Leukemia.

Authors:  Ruiqing Zhou; Wenjian Mo; Shunqing Wang; Wei Zhou; Xiaowei Chen; Shiyi Pan
Journal:  Cell Transplant       Date:  2019-11-14       Impact factor: 4.064

Review 10.  Epi-miRNAs: Regulators of the Histone Modification Machinery in Human Cancer.

Authors:  Deniz Mortazavi; Behnoush Sohrabi; Meysam Mosallaei; Ziba Nariman-Saleh-Fam; Milad Bastami; Yaser Mansoori; Abdolreza Daraei; Sepideh Zununi Vahed; Shadan Navid; Zahra Saadatian; Tannaz Jamialahmadi; Yong Teng; Amirhossein Sahebkar
Journal:  J Oncol       Date:  2022-01-11       Impact factor: 4.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.